首页> 外文OA文献 >Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

【2h】

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

机译：复发性多发性硬化症中达克里珠单抗高产过程与肌内干扰素β-1a随机，双盲，主动比较器的皮肤不良事件决定研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis [J] . Krueger James G., Kircik Leon, Hougeir Firas, Advances in therapy. . 2016,第7期

机译：皮肤性不良事件在随机，双盲，主动比较器中决定达格珠单抗高产过程与肌注干扰素Beta-1a在复发缓解型多发性硬化症中的作用
2. No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study [J] . Kappos Ludwig, Havrdova Eva, Giovannoni Gavin, Multiple sclerosis: clinical and laboratory research . 2017,第13期

机译：没有患者接受Daclizumab与肌内干扰素β-1A的患者疾病活动的证据，用于在决定研究中重复延迟多发性硬化
3. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (see comments) [J] . The Lancet . 1998,第9139期

机译：干扰素β-1a在复发/缓解多发性硬化症中的随机双盲安慰剂对照研究。 PRISMS（通过干扰素β-1a皮下预防多发性硬化症复发和残疾）研究组（请参阅评论）
4. Cutaneous Adverse Events in the Randomized Double-Blind Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis [O] . James G. Krueger, Leon Kircik, Firas Hougeir, -1

机译：反复双盲主动比较器中的皮肤不良事件决定了达克珠单抗高产过程与反复发作的多发性硬化症中肌注干扰素β-1a的关系
5. Cost-Effectiveness of Daclizumab Versus Interferon Beta-1A in the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis in the United States [O] . D Rao, E Heidari, KM Kamal, 2018

机译：Daclizumab与干扰素β-1a的成本效果治疗在美国复发延迟多发性硬化患者中的治疗

Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis

著录项

引文网络

相似文献

相关主题

期刊订阅